10x Genomics Inc (NASDAQ: TXG) on Tuesday, plunged -2.00% from the previous trading day, before settling in for the closing price of $12.47. Within the past 52 weeks, TXG’s price has moved between $6.78 and $24.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -36.10%. The company achieved an average annual earnings per share of 19.09%. With a float of $105.63 million, this company’s outstanding shares have now reached $109.08 million.
The extent of productivity of a business whose workforce counts for 1306 workers is very important to gauge. In terms of profitability, gross margin is 68.79%, operating margin of -27.6%, and the pretax margin is -24.56%.
10x Genomics Inc (TXG) Insider Updates
Observing investor behavior towards Health Information Services industry stocks is more important than anything else. The insider ownership of 10x Genomics Inc is 15.39%, while institutional ownership is 90.18%. The most recent insider transaction that took place on May 22 ’25, was worth 77,540. In this transaction Chief Executive Officer of this company sold 9,343 shares at a rate of $8.30, taking the stock ownership to the 1,083,625 shares. Before that another transaction happened on May 22 ’25, when Company’s insider sold 7,485 for $8.30, making the entire transaction worth $62,120. This insider now owns 448,374 shares in total.
10x Genomics Inc (TXG) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 19.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.74% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
10x Genomics Inc (TXG) is currently performing well based on its current performance indicators. A quick ratio of 4.68 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.44. Likewise, its price to free cash flow for the trailing twelve months is 33.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.30, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
The latest stats from [10x Genomics Inc, TXG] show that its last 5-days average volume of 2.9 million was inferior to 3.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 60.51%.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 85.53%, which indicates a significant increase from 63.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.78 in the past 14 days, which was higher than the 0.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.24, while its 200-day Moving Average is $12.72. Now, the first resistance to watch is $12.62. This is followed by the second major resistance level at $13.01. The third major resistance level sits at $13.26. If the price goes on to break the first support level at $11.98, it is likely to go to the next support level at $11.73. Assuming the price breaks the second support level, the third support level stands at $11.34.
10x Genomics Inc (NASDAQ: TXG) Key Stats
Market capitalization of the company is 1.53 billion based on 123,134K outstanding shares. Right now, sales total 610,790 K and income totals -182,630 K. The company made 154,880 K in profit during its latest quarter, and -34,360 K in sales during its previous quarter.
